Hongjidi

Hongjidi Uses, Dosage, Side Effects, Food Interaction and all others data.

Hongjidi is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.

Hongjidi is a pro-drug which is converted non-enzymatically during intestinal absorption into the microbiologically active moiety erythromycylamine. Erythromycylamine exerts its activity by binding to the 50S ribosomal subunits of susceptible mircoorganisms resulting in inhibition of protein synthesis. Hongjidi/erythromycylamine has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections: Staphylococcus aureus (methicillin-susceptible strains only), Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, and Mycoplasma pneumoniae.

Hongjidi
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Hongjidi
Availability	Discontinued
Generic	Dirithromycin
Dirithromycin Other Names	Dirithromycin, Dirithromycine, Dirithromycinum, Diritromicina
Related Drugs	amoxicillin, doxycycline, ciprofloxacin, cephalexin, metronidazole, azithromycin, clindamycin, ceftriaxone, levofloxacin, Augmentin
Type
Formula	C₄₂H₇₈N₂O₁₄
Weight	Average: 835.086 Monoisotopic: 834.5453052
Protein binding	15 to 30% for erythromycylamine, the active compound.
Groups	Experimental
Therapeutic Class
Manufacturer
Available Country	China
Last Updated:	September 19, 2023 at 7:00 am

Uses

Hongjidi is an antibiotic used to treat a variety of respiratory, skin, and other infections.

For the treatment of the following mild-to-moderate infections caused by susceptible strains of microorganisms: acute bacterial exacerbations of chronic bronchitis, secondary bacterial infection of acute bronchitis, community-acquired pneumonia, pharyngitis/tonsilitis, and uncomplicated skin and skin structure infections.

Hongjidi is also used to associated treatment for these conditions: Acute Exacerbation of Chronic Bronchitis (AECB), Community Acquired Pneumonia (CAP), Lower Respiratory Tract Infection (LRTI), Pharyngitis, Secondary Infection, Skin and Soft Tissue Infections, Tonsillitis, Upper Respiratory Tract Infection

How Hongjidi works

Hongjidi prevents bacteria from growing, by interfering with their protein synthesis. Hongjidi binds to the 50S subunit of the 70S bacterial ribosome, and thus inhibits the translocation of peptides. Hongjidi has over 10 times higher affinity to the subunit 50S than erythromycin. In addition, dirithromycin binds simultaneously in to two domains of 23S RNA of the ribosomal subunit 50S, where older macrolides bind only in one. Hongjidi can also inhibit the formation of ribosomal subunits 50S and 30S.

Toxicity

The toxic symptoms following an overdose of a macrolide antibiotic may include nausea, vomiting, epigastric distress, and diarrhea.

Hongjidi Drug Interaction

Minor: penicillin g benzathine / procaine penicillin, penicillin g benzathine / procaine penicillinUnknown: anagrelide, anagrelide, mannitol, mannitol, aspirin, aspirin, azathioprine, azathioprine, iobenguane I 131, iobenguane I 131, loratadine / pseudoephedrine, loratadine / pseudoephedrine, dantrolene, dantrolene, phenytoin, phenytoin, dimercaptosuccinic acid, dimercaptosuccinic acid

Hongjidi Disease Interaction

Major: colitis, QT prolongationModerate: liver disease

Elimination Route

Oral dirithromycin is rapidly absorbed, with an absolute bioavailability of approximately 10%. Dietary fat has little or no effect on the bioavailability of dirithromycin.

Half Life

The mean plasma half-life of erythromycylamine was estimated to be about 8 h (2 to 36 h), with a mean urinary terminal elimination half-life of about 44 h (16 to 65 h) in patients with normal renal function.